The role of pro-drug therapy in the treatment of cancer

M. J. Ferguson, Fazle Ahmed, J. Cassidy

    Research output: Contribution to journalArticle

    20 Citations (Scopus)

    Abstract

    The administration of anti-cancer agents is currently associated with significant toxicity and lack of tumour specificity. Prodrugs are being designed to favourably alter the therapeutic index of these agents by improving their efficacy and reducing toxicity Progress in the development of prodrugs including the cytotoxic agents most commonly used in cancer treatments namely 5-fluorouracil (5-FU), the anthracyclines, paclitaxel and platinum will be described. Many of these agents are at an early stage of development: however, this article will also describe those which have already made an impact in the clinic. It is likely that future improvements in care will come from refinement of the drugs already well established in clinical practice. In addition, this technology could be applied to novel agents with alternative cellular targets such as those involved in angiogenesis or in conferring metastatic potential. Thus, lessons learned with standard drugs may be applicable across a wider spectrum of therapeutics. (C) 2001 Harcourt Publishers Ltd.

    Original languageEnglish
    Pages (from-to)225-232
    Number of pages7
    JournalDrug Resistance Updates
    Volume4
    Issue number4
    DOIs
    Publication statusPublished - 2001

    Keywords

    • PROSTATE-SPECIFIC ANTIGEN
    • L-LEUCYL-DOXORUBICIN
    • PRELIMINARY IN-VITRO
    • ANTITUMOR-ACTIVITY
    • POLYETHYLENE-GLYCOL
    • PHASE-I
    • N-(2-HYDROXYPROPYL)METHACRYLAMIDE COPOLYMERS
    • POLY(ETHYLENE GLYCOL)
    • PACLITAXEL CONJUGATE
    • 5-FLUOROURACIL 5-FU

    Cite this

    The role of pro-drug therapy in the treatment of cancer. / Ferguson, M. J.; Ahmed, Fazle; Cassidy, J.

    In: Drug Resistance Updates, Vol. 4, No. 4, 2001, p. 225-232.

    Research output: Contribution to journalArticle

    Ferguson, M. J. ; Ahmed, Fazle ; Cassidy, J. / The role of pro-drug therapy in the treatment of cancer. In: Drug Resistance Updates. 2001 ; Vol. 4, No. 4. pp. 225-232.
    @article{6fd1361bfa5446e88b191096254c0b7c,
    title = "The role of pro-drug therapy in the treatment of cancer",
    abstract = "The administration of anti-cancer agents is currently associated with significant toxicity and lack of tumour specificity. Prodrugs are being designed to favourably alter the therapeutic index of these agents by improving their efficacy and reducing toxicity Progress in the development of prodrugs including the cytotoxic agents most commonly used in cancer treatments namely 5-fluorouracil (5-FU), the anthracyclines, paclitaxel and platinum will be described. Many of these agents are at an early stage of development: however, this article will also describe those which have already made an impact in the clinic. It is likely that future improvements in care will come from refinement of the drugs already well established in clinical practice. In addition, this technology could be applied to novel agents with alternative cellular targets such as those involved in angiogenesis or in conferring metastatic potential. Thus, lessons learned with standard drugs may be applicable across a wider spectrum of therapeutics. (C) 2001 Harcourt Publishers Ltd.",
    keywords = "PROSTATE-SPECIFIC ANTIGEN, L-LEUCYL-DOXORUBICIN, PRELIMINARY IN-VITRO, ANTITUMOR-ACTIVITY, POLYETHYLENE-GLYCOL, PHASE-I, N-(2-HYDROXYPROPYL)METHACRYLAMIDE COPOLYMERS, POLY(ETHYLENE GLYCOL), PACLITAXEL CONJUGATE, 5-FLUOROURACIL 5-FU",
    author = "Ferguson, {M. J.} and Fazle Ahmed and J. Cassidy",
    year = "2001",
    doi = "10.1054/drup.2001.0207",
    language = "English",
    volume = "4",
    pages = "225--232",
    journal = "Drug Resistance Updates",
    issn = "1368-7646",
    publisher = "Churchill Livingstone",
    number = "4",

    }

    TY - JOUR

    T1 - The role of pro-drug therapy in the treatment of cancer

    AU - Ferguson, M. J.

    AU - Ahmed, Fazle

    AU - Cassidy, J.

    PY - 2001

    Y1 - 2001

    N2 - The administration of anti-cancer agents is currently associated with significant toxicity and lack of tumour specificity. Prodrugs are being designed to favourably alter the therapeutic index of these agents by improving their efficacy and reducing toxicity Progress in the development of prodrugs including the cytotoxic agents most commonly used in cancer treatments namely 5-fluorouracil (5-FU), the anthracyclines, paclitaxel and platinum will be described. Many of these agents are at an early stage of development: however, this article will also describe those which have already made an impact in the clinic. It is likely that future improvements in care will come from refinement of the drugs already well established in clinical practice. In addition, this technology could be applied to novel agents with alternative cellular targets such as those involved in angiogenesis or in conferring metastatic potential. Thus, lessons learned with standard drugs may be applicable across a wider spectrum of therapeutics. (C) 2001 Harcourt Publishers Ltd.

    AB - The administration of anti-cancer agents is currently associated with significant toxicity and lack of tumour specificity. Prodrugs are being designed to favourably alter the therapeutic index of these agents by improving their efficacy and reducing toxicity Progress in the development of prodrugs including the cytotoxic agents most commonly used in cancer treatments namely 5-fluorouracil (5-FU), the anthracyclines, paclitaxel and platinum will be described. Many of these agents are at an early stage of development: however, this article will also describe those which have already made an impact in the clinic. It is likely that future improvements in care will come from refinement of the drugs already well established in clinical practice. In addition, this technology could be applied to novel agents with alternative cellular targets such as those involved in angiogenesis or in conferring metastatic potential. Thus, lessons learned with standard drugs may be applicable across a wider spectrum of therapeutics. (C) 2001 Harcourt Publishers Ltd.

    KW - PROSTATE-SPECIFIC ANTIGEN

    KW - L-LEUCYL-DOXORUBICIN

    KW - PRELIMINARY IN-VITRO

    KW - ANTITUMOR-ACTIVITY

    KW - POLYETHYLENE-GLYCOL

    KW - PHASE-I

    KW - N-(2-HYDROXYPROPYL)METHACRYLAMIDE COPOLYMERS

    KW - POLY(ETHYLENE GLYCOL)

    KW - PACLITAXEL CONJUGATE

    KW - 5-FLUOROURACIL 5-FU

    U2 - 10.1054/drup.2001.0207

    DO - 10.1054/drup.2001.0207

    M3 - Article

    VL - 4

    SP - 225

    EP - 232

    JO - Drug Resistance Updates

    JF - Drug Resistance Updates

    SN - 1368-7646

    IS - 4

    ER -